Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles OncoImmunology Year : 2021

Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response

Abstract

The antibody-dependent cellular cytotoxicity (ADCC) effector function of natural killer (NK) cells is one of the known mechanisms of action for rituximab-based anti-cancer immunotherapy. Inhibition of the ADCC function of NK cells through interactions between inhibitory killer cell immunoglobulin-like receptors (KIRs) and HLA class I ligands is associated with resistance of cancers to rituximab. In this study, we deeply investigated the impact of KIR, HLA class I, and CD16 genotypes on rituximab-dependent NK cell responses in both an in vitro cellular model from healthy blood donors and ex vivo rituximab-treated non-Hodgkin lymphoma (NHL) patients. We highlight that an HLA environment with limited KIR ligands is beneficial to promoting a higher frequency of KIR+ NK cells including both educated and uneducated NK cells, two NK cell compartments that demonstrate higher rituximab-dependent degranulation than KIR- NK cells. In contrast, a substantial KIR ligand environment favors a higher frequency of poorly effective KIR- NK cells and numerous functional KIR/HLA inhibitions of educated KIR+ NK cells. These phenomena explain why NHL patients with limited KIR ligands respond better to rituximab. In this HLA environment, CD16 polymorphism appears to have a collateral effect. Furthermore, we show the synergic effect of KIR2DS1, which strongly potentiates NK cell ADCC from C2- blood donors against C2+ target cells. Taken together, these results pave the way for stronger prediction of rituximab responses for NHL patients. HLA class I typing and peripheral blood KIR+ NK cell frequency could be simple and useful markers for predicting rituximab response.

Domains

Cancer
Fichier principal
Vignette du fichier
OncoImmunol2021Eq1.pdf (2.31 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

inserm-03287975 , version 1 (16-07-2021)

Identifiers

Cite

Dhon Roméo Makanga, Maxime Jullien, Gaëlle David, Nolwenn Legrand, Catherine Willem, et al.. Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response. OncoImmunology, 2021, 10 (1), pp.1936392. ⟨10.1080/2162402x.2021.1936392⟩. ⟨inserm-03287975⟩
67 View
58 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More